Aditya Bahl’s Post

🗞️ Last week’s Pharma industry news in Germany and Switzerland 🗞️  CENTOGENE: Research published in Science unveils insights into human pre-TCRα deficiency, revealing its prevalence and implications for autoimmunity. MoonLake Immunotherapeutics (NASDAQ: MLTX): Announced positive 2023 financial results and successful Phase 2 trials for sonelokimab, indicating significant business progress. Oculis: Shared updates on late-stage clinical trials for eye treatments at R&D Day and announced significant leadership appointments. Idorsia Pharmaceuticals Ltd and Viatris: Entered a significant global R&D collaboration for cardiovascular and autoimmune diseases, highlighting a strategic partnership. QIAGEN: Launched a new AI-powered biomedical knowledge base to accelerate data-driven drug research through comprehensive analysis. Sandoz: Acquired CIMERLI® from Coherus BioSciences, enhancing its biosimilar and ophthalmology portfolio in the US market. Novartis: Presented new data on Zolgensma, demonstrating its safety and efficacy in older and heavier children with SMA. #pharmaceuticalindustry #pharma #Monday_Pharma_News

At Silo Pharma, we are developing treatments such as SPC-15 for those living with #PTSD. We recognize the urgency for effective treatment options, and we're actively pursuing preclinical work with our data that indicates that SPC-15 could have additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels. We anticipate that our pre-IND submission will lead to valuable guidance from the FDA as we prepare for the first-in-human clinical trial of SPC-15 in PTSD. Stay tuned for further updates on our clinical roadmap. #PTSDResearch #MentalHealthMatters #Biopharmaceuticals

Precision functional mapping is revolutionizing the field of drug development by enhancing our understanding of target engagement at the molecular level. This approach involves detailed mapping of the interactions between a drug candidate and its biological targets, providing critical insights into the drug's mechanism of action. By precisely identifying which pathways and cellular functions are modulated, researchers can optimize drug design and improve therapeutic efficacy. Precision functional mapping allows for the early identification of potential off-target effects, reducing the likelihood of adverse reactions and improving patient safety. I think this advanced technique will continue to accelerate the drug development process, increase the success rate of clinical trials, and lead to the creation of more effective and safer medications for patients in need. With over 70,000 ICD-10 codes (International Classification of Disease), there is still a lot of work to be done. #Pharma #Medicine #Healthcare #Innovation #DrugDevelopment #ClinicalTrails

𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report provides an overview of the development of the Radiopharmaceuticals industry chain, covering the market status of Oncology (Diagnostic Radioisotopes, Therapeutic Radioisotopes) and Cardiology (Diagnostic Radioisotopes, Therapeutic Radioisotopes), along with key enterprises in both developed and developing markets. It analyzes cutting-edge technology, patents, hot applications, and market trends in Radiopharmaceuticals. Regionally, the report examines Radiopharmaceuticals markets in key regions, noting steady growth in North America and Europe due to government initiatives and increased consumer awareness. In Asia-Pacific, particularly in China, the market leads globally with strong domestic demand, supportive policies, and a robust manufacturing base. The Radiopharmaceuticals market is segmented by Type and Application, providing accurate calculations and forecasts for consumption value by Type and Application in terms of volume and value for the period 2024-2031. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/digMcPkN *𝗕𝘆 𝗧𝘆𝗽𝗲: Diagnostic Radioisotopes, Therapeutic Radioisotopes *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Oncology, Cardiology, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Bracco Imaging do Brasil, Mallinckrodt Pharmaceuticals, Nordion, TRIAD ISOTOPES MACON, Lantheus, GE HealthCare, China Isotope & Radiation Corp, Jubilant Pharma Limited, Eli Lilly and Company, Advanced Accelerator Applications, Siemens Healthineers, DONGCHENG LI, Navidea Biopharmaceuticals #radiopharmaceuticals #nuclearmedicine #medicalimaging #radiotherapy #healthcare #cancertreatment #medicalinnovation #diagnosticimaging #radiology #pharmaceuticals #nucleardiagnostics #patientcare #cancerdiagnosis #radiopharmacy #healthtech #oncology #radiotracers #clinicalresearch #molecularimaging #healthyliving #theranostics #medicalresearch #imagingtechnology #radiologicalhealth #healthcareinnovation #advancedmedicine #precisionmedicine #cancercare #medicaladvancements #radiationtherapy

📞 Call for Business Enquiries: +91-8708402647 🌐 Explore more at www.fibovil.com Exploring Biotech Advancements: Spotlight on Fibovil Pharmaceuticals In the rapidly evolving field of biotechnology, innovation is the driving force behind transformative healthcare solutions. This blog delves into the world of top biotech companies, with a special focus on Fibovil Pharmaceuticals and its significant contributions to the industry. Top Biotech Companies: Leading the Healthcare Revolution Biotechnology continues to redefine healthcare through groundbreaking discoveries and advanced therapeutic approaches. Leading biotech firms are pioneers in leveraging biological processes to develop novel treatments across a spectrum of medical disciplines. These companies combine scientific expertise with cutting-edge technology to push the boundaries of medical innovation. Fibovil Pharmaceuticals: A Beacon of Innovation Among these top biotech companies stands Fibovil Pharmaceuticals, renowned for its unwavering commitment to innovation and scientific excellence. Specializing in the development of advanced therapies, Fibovil addresses critical medical needs in areas such as oncology, neurology, and rare diseases. Through rigorous research and development efforts, Fibovil has earned acclaim for its transformative impact on healthcare solutions. Innovative Achievements and Contributions Fibovil Pharmaceuticals has achieved significant milestones across multiple therapeutic domains. In oncology, the company pioneers precision therapies aimed at improving treatment outcomes and patient quality of life. Their initiatives in neurology focus on innovative approaches to managing neurological disorders, promising advancements that enhance patient care and well-being.#fibovil #covaxl #cardix #derma #cardiac #critical #pcd #pharmafranchise#winovulation #franchisecompany #pcdpharma #Intralife #pharmapcdfranchise #franchiseinindia #monopolybasispharmafranchise #pharmafranchiseinnashik #distributorship #franchisepartner #howtostartpcdfranchise #bestpharmaceuticalcompany #pharmaceutical #investinpharmafranchise 

🧠 𝗟𝗶𝗽𝗶𝗱-𝗯𝗮𝘀𝗲𝗱 𝗡𝗮𝗻𝗼𝗰𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗡𝗦 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 💊 🔵 Lipid-based nanocarriers have shown significant potential in crossing the blood-brain barrier (BBB) to deliver therapeutics to the CNS. 🔵 Studies indicate that these nanocarriers can improve drug delivery efficiency to the brain by up to 💯-fold compared to free drugs. This enhanced delivery is crucial for treating neurological disorders such as #Alzheimer's disease and #Parkinson's disease, which affect over 50 million and 10 million people worldwide, respectively. 🔵 Moreover, lipid-based nanoparticles have demonstrated the ability to increase drug bioavailability in the brain, with some formulations achieving brain uptake levels of over 5% of the injected dose, compared to less than 1% with conventional methods. 🔵Do you have any experience with using Lipid-based nanocarriers? Our characterization services are customized to fit your development stage and budget! ------------------------------------------------------- 📨 Contact us today to learn more! TechnoPharmaSphere #brain #drugdelivery #cns #centralnervoussystem #medicine #drugs #biopharma #pharmaceuticals #biotechnology

AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's Alzecure shares promising clinical results for NeuroRestore ACD856 in Alzheimer's treatment. These strides offer hope for a breakthrough therapeutic solution against Alzheimer's. #Alzecure #NeuroRestore #AlzheimersResearch #ClinicalTrials #MedicalInnovation #HealthcareTech #pharma #biotech #pharmiwebcom

#𝐆𝐥𝐨𝐛𝐚𝐥 #𝐆𝐢𝐚𝐧𝐭 #𝐂𝐞𝐥𝐥 #𝐀𝐫𝐭𝐞𝐫𝐢𝐭𝐢𝐬 #𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 #𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 1.63 𝐁𝐧. 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 6 % 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 2030. 𝐓𝐨 𝐝𝐢𝐯𝐞 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐬, 𝐜𝐥𝐢𝐜𝐤 𝐭𝐡𝐞 𝐛𝐞𝐥𝐨𝐰 𝐥𝐢𝐧𝐤:  https://lnkd.in/ePDcgvQY The giant cell arteritis (GCA) therapeutics market is expanding as awareness and diagnosis of this inflammatory disease increase. #Giant cell arteritis, also known as temporal arteritis, primarily affects the elderly and involves inflammation of the blood vessels, which can lead to serious complications such as vision loss if not promptly treated. The market #growth is driven by advancements in diagnostic techniques, allowing for earlier and more accurate identification of the condition. Additionally, the introduction of novel #therapies, including biologics and corticosteroids, is providing patients with more effective treatment options, enhancing disease management and patient outcomes. The #GCA therapeutics market is also benefiting from increased research and development efforts focused on understanding the underlying mechanisms of the disease and identifying new therapeutic targets. Pharmaceutical companies and research institutions are investing in clinical trials to explore the efficacy of emerging treatments, including targeted #biologics that address specific pathways involved in inflammation. The growing elderly population, particularly in developed regions, is further contributing to market demand, as the incidence of GCA tends to increase with age. As a result, the market for GCA #therapeutics is poised for continued growth, driven by ongoing advancements in treatment options and a greater emphasis on improving patient quality of life. 𝑪𝒐𝒎𝒑𝒆𝒕𝒊𝒕𝒊𝒗𝒆 𝑳𝒂𝒏𝒅𝒔𝒄𝒂𝒑𝒆: 1. Sanofi 2. Kiniksa Pharmaceuticals, Ltd. 3. Regeneron 4. GlaxoSmithKline Consumer Healthcare, L.P. 5. Johns Hopkins Medicine 6. Novartis 7. AbbVie 8. Bristol Myers Squibb 9. Abbott 10.Johnson & Johnson #𝐆𝐢𝐚𝐧𝐭𝐂𝐞𝐥𝐥𝐀𝐫𝐭𝐞𝐫𝐢𝐭𝐢𝐬 #𝐆𝐂𝐀𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 #𝐓𝐞𝐦𝐩𝐨𝐫𝐚𝐥𝐀𝐫𝐭𝐞𝐫𝐢𝐭𝐢𝐬 #𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲𝐃𝐢𝐬𝐞𝐚𝐬𝐞 #𝐄𝐥𝐝𝐞𝐫𝐥𝐲𝐂𝐚𝐫𝐞 #𝐕𝐢𝐬𝐢𝐨𝐧𝐋𝐨𝐬𝐬𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 #𝐂𝐨𝐫𝐭𝐢𝐜𝐨𝐬𝐭𝐞𝐫𝐨𝐢𝐝𝐬 #𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 #𝐌𝐞𝐝𝐢𝐜𝐚𝐥𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 #𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 #𝐂𝐡𝐫𝐨𝐧𝐢𝐜𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 #𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 #𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐓𝐫𝐢𝐚𝐥𝐬 #𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐂𝐚𝐫𝐞 #𝐀𝐠𝐢𝐧𝐠𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧

FDA's Office of New Drugs (OND) Research Outcomes Report for FY2022-2023! This comprehensive report highlights the significant strides made in regulatory science, aimed at improving new drug approval processes and addressing unmet medical needs. Key Highlights: 1.Research Contributions: Over 80 external presentations and 94 peer-reviewed publications showcasing groundbreaking work in various therapeutic areas. 2.Innovative Projects: a.Development of clinical outcome assessments for rare diseases. b.Physiologically-based pharmacokinetic modeling for predicting fetal exposure to maternal drugs. c.Advancements in pediatric oncology and acute pain treatment strategies. 3.Regulatory Impacts: 33 outcomes that directly facilitated regulatory decision-making, including new drug development tools and internal policies. Read the full report #FDA #DrugDevelopment #ClinicalResearch #RegulatoryScience #Innovation #Healthcare

In the rapidly evolving field of medicine, developing new therapeutic strategies is crucial for addressing complex diseases that single-agent treatments often fail to manage effectively. This webinar will delve into the intricate landscape of combination drug therapy, exploring the scientific, regulatory, and commercial challenges involved, while also highlighting the significant potential for improved patient outcomes and market growth. Participants will have the opportunity to gain insights from leading experts on the latest advancements in pharmacology and clinical trial design. The session will focus on how combination therapies can address the multifaceted mechanisms of diseases, offering new avenues for treatment.